[Pre-Aug 2018] IMSCAR
- Cyhoeddwyd
Orphan drugs revisited: author's response.
Hughes, D. & Hughes, D. A., 1 Mai 2006, Yn: Quarterly Journal of Medicine. 99, 5, t. 350-351Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
The British antibiotic and silver-impregnated catheters for ventriculoperitoneal shunts multi-centre randomised controlled trial (the BASICS trial): study protocol
Hughes, D., Jenkinson, M. D., Gamble, C., Hartley, J. C., Hickey, H., Hughes, D. A., Blundell, M., Griffiths, M. J., Solomon, T. & Malluci, C. L., 3 Ion 2014, Yn: Trials. 15, 14Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?
Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Awst 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.
Hughes, D., Hughes, D. A. & Walley, T., 1 Gorff 2003, Yn: Clinical Pharmacology and Therapeutics. 74, 1, t. 1-8Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?
Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Investigating factors influencing user choices to visit either general practioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment.
Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Charitable contributions to funding cancer services for children and young people in England and Wales
Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2008, Yn: Journal of Child Health Care. 12, 2, t. 156-168Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial
Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Tach 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.
Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
AWMSG criteria for appraising new medicines.
Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence
Hughes, D., Plumpton, C. O., Brown, I., Reuber, M., Marson, A. G. & Hughes, D. A., 26 Maw 2015, Yn: Epilepsy and Behavior. 45, t. 180-186Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.
Hughes, D., Jorgensen, A. L., Al-Zubiedi, S., Zhang, J. E., Keniry, A., Hanson, A., Hughes, D. A., Van Eker, D., Stevens, L., Hawkins, K., Toh, C. H., Kamali, F., Daly, A. K., Fitzmaurice, D., Coffey, A., Williamson, P. R., Park, B. K., Deloukas, P. & Pirmohamed, M., 1 Hyd 2009, Yn: Pharmacogenetics and Genomics. 19, 10, t. 800-812Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Pharmacokinetics, patient compliance and pharmaeconomics
Hughes, D. & Hughes, D. A., 1 Meh 2005.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics
Hughes, D. & Hughes, D. A., 1 Mai 2002.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.
Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Patient compliance and pharmacoeconomics
Hughes, D. & Hughes, D. A., 1 Hyd 2001.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Economic evaluation of steroid injections (methylprednisolone) in the treatment of Morton's neuroma: patient-blind randomised trial
Hughes, D., Thomson, C., Beggs, I., Martin, D., McCaldin, D., Russell, D., Edwards, R. T., Hughes, D. A., Yeo, S. T., Russell, I. T. & Gibson, T. N., 1 Maw 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.
Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Hyd 2001, Yn: Health Economics. 10, 7, t. 601-615Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
The development of a QALY measure for epilepsy: NEWQOL-6D
Hughes, D., Mulhern, B., Rowen, D., Jacoby, A., Marson, T., Snape, D., Hughes, D. A., Latimer, N., Baker, G. A. & Brazier, J. E., 1 Mai 2012, Yn: Epilepsy and Behavior. 24, 1, t. 36-43Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Pharmacoeconomics appraisals by the all Wales medicines strategy group
Hughes, D. & Hughes, D. A., 1 Gorff 2004.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.
Hughes, D. & Hughes, D. A., 1 Gorff 2005, Yn: European Journal of Cancer. 41, 11, t. 1655Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
The difference between effectiveness and efficacy of antimalarial drugs in Kenya.
Hughes, D., Amin, A. A., Hughes, D. A., Marsh, V., Abuya, T. O., Kokwaro, G. O., Winstanley, P. A., Ochala, S. A. & Snow, R. W., 1 Medi 2004, Yn: Tropical Medicine and International Health. 9, 9, t. 967-974Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance
Hughes, D., Hughes, D. A. & Walley, T., 1 Medi 2001.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Introduction to pharmaeconomics
Hughes, D. & Hughes, D. A., 1 Gorff 2004.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes
Hughes, D., Farmer, A., Hardeman, W., Hughes, D. A., Prevost, A. T., Kim, Y., Craven, A., Oke, J., Boase, S., Selwood, M., Kellar, I., Graffy, J., Griffin, S., Sutton, S. & Kinmonth, A. L., 5 Ebr 2012, Yn: BMC Family Practice. 13, 30Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations.
Hughes, D., Hughes, D. A., Tilson, L. & Drummond, M. F., 1 Mai 2009, Yn: Pharmacoeconomics. 27, 8, t. 635-643Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands
Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Tach 2004.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Defining rewardable innovation in drug therapy
Hughes, D., Aronson, J. K., Ferner, R. E. & Hughes, D. A., 1 Ebr 2012, Yn: Nature Reviews Drug Discovery. 11, t. 253-254Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Statistical comments are unfounded.
Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Maw 2008, Yn: Value in Health. 11, 2, t. 346Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Pharmacoeconomics of pharmacogenetic testing: azathioprine
Hughes, D., McAllister, R. & Hughes, D. A., 1 Ebr 2004.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
A systematic review and empirical analysis of the relation between dose and duration of drug action.
Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Ion 2009, t. TP40.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Maw 2010, Yn: Clinical Pharmacology and Therapeutics. 87, 3, t. 257-261Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Orphan drug treatments: economic considerations
Hughes, D. & Hughes, D. A., 1 Tach 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Welsh Health Economics Network (WHEN): Scoping Report.
Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Evaluation of a consultant audit and feedback programme to improve the quality of antimicrobial prescribing in acute medical admissions
Hughes, D., Roberts, E., Dawoud, D. M., Hughes, D. A. & Cefai, C., 1 Hyd 2015, Yn: International Journal of Pharmacy Practice. 23, 5, t. 333-339Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Public funding of drugs for orphan diseases
Hughes, D. & Hughes, D. A., 1 Tach 2005.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Integrating compliance and persistence in health economics models
Hughes, D. & Hughes, D. A., 1 Ion 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Impact of non-compliance on the cost-effectiveness of statin therapy
Hughes, D., Hughes, D. A. & Bagust, A., 1 Medi 2001, Yn: Value in Health. 4, 6, t. 489Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.
Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Ion 2004, Yn: Drug Safety. 27, 8, t. 535-554Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
The future challenges
Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 167-174Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod
- Cyhoeddwyd
Engaging with the MRC Methodology Hubs – NWHTMR.
Hughes, D. & Hughes, D. A., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Economic impact of poor compliance with pharmaceuticals.
Hughes, D. & Hughes, D. A., 1 Awst 2002, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, t. 327-335Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009, t. O41.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.
Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Ion 2001, 2001 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Public meetings of the NICE appraisals committee
Hughes, D. & Hughes, D. A., 1 Rhag 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Pharmacoeconomic models that incorporate non-compliance
Hughes, D. & Hughes, D. A., 1 Gorff 2004.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment
Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Meh 2006.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?
Hughes, D. & Hughes, D. A., 1 Tach 2006.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Quantitative risk-benefit analysis
Hughes, D. & Hughes, D. A., 1 Mai 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
The pharmacokinetic profile of Warfarn: a systematic review
Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Rhag 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Warfarin pharmacogenetics: Economic considerations.
Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Ion 2007, Yn: Pharmacoeconomics. 25, 11, t. 899-902Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Use of PK-PD modelling to predict the impact of non-compliance
Hughes, D. & Hughes, D. A., 1 Tach 2003.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.
Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Multiple imputation of multiple multi-item scales when a full imputation model is infeasible
Hughes, D., Plumpton, C. O., Morris, T., Hughes, D. A. & White, I. R., 26 Ion 2016, Yn: BMC Research Notes. 9, 45, t. 1-15Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.
Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2005, 2005 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?
Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Awst 2007, Yn: Clinical Pharmacology and Therapeutics. 82, 2, t. 123-127Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design
Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Maw 2006.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.
Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Adverse drug reactions in economic evaluations
Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity
Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Meh 2004, Yn: Pharmacogenetics. 14, 6, t. 335-342Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Methodological issues in the literature on costs of non-compliance in chronic diseases
Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
Hughes, D., Pink, J., Lane, S., Pirmohamed, M. & Hughes D.A., N. V., 31 Hyd 2011, Yn: British Medical Journal. 343, t. 1-14Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?
Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Pharmacogenetic tests: the need for a level playing field
Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Ion 2013, Yn: Nature Reviews Drug Discovery. 12, 3-4Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Drug compliance and pharmaceconomics
Hughes, D. & Hughes, D. A., 1 Rhag 2003.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Economic evaluation during early (phase II) trials
Hughes, D. & Hughes, D. A., 1 Tach 2002.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis
Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 Mai 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.
Hughes, D., Hughes, D. A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 11, t. 1069-1077Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)
Hughes, D., Ramanan, A., Dick, A. D., Benton, D., Compeyrot-Lacassagne, S., Dawoud, D., Hardwick, B., Hickey, H., Hughes, D. A., Jones, A., Woo, P., Edelsten, C., Beresford, M. W. & The SYCAMORE Trail Management Group, N. V., 9 Ion 2014, Yn: Trials. 15, 14Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Abolition of prescription copayments in Wales: an observational study on dispensing rates.
Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Awst 2010, Yn: Value in Health. 13, 5, t. 675-680Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Effects of the abolition of prescription charges in Wales: A preliminary analysis
Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Ebr 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales
Hughes, D. & Hughes, D. A., 1 Tach 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
The economics of evergreening.
Hughes, D. & Hughes, D. A., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.
Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Tach 2007, Yn: Value in Health. 10, 6, t. 498-509Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
A prototype agent-based model of antimalarial drug compliance
Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Awst 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Back to basics: what is the relationship between dose and duration of drug action?
Hughes, D. & Hughes, D. A., 1 Mai 2006.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals: Pharmacokinetic/Pharmacodynamic/Pharmacoeconomic Analysis of Rituximab for Follicular Lymphoma.
Hughes, D., Pink, J., Lane, S. & Hughes, D. A., 19 Maw 2012, Yn: Pharmacoeconomics.Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?
Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 Mai 2007.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Is exercise effective in promoting mental well-being in older age? A systematic review.
Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T. & Woods, R. T., 1 Awst 2010, Yn: Aging and Mental Health. 14, 6, t. 652-669Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
Hughes, D., Verhof, T. I., Redekop, W. K., van Schie, R. M., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L. A., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A. & Maitland-van der Zee, A. H., 1 Medi 2012, Yn: Pharmacogenomics. 13, 12, t. 1405-1417Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
The problem of orphan drugs
Hughes, D., Ferner, R. E. & Hughes, D. A., 16 Tach 2010, Yn: British Medical Journal. 341, t. 335-341Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid